We are live on ! Find out more
COCP icon

Cocrystal Pharma

21 hedge funds and large institutions have $8.39M invested in Cocrystal Pharma in 2020 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 5 increasing their positions, 2 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

162% more capital invested

Capital invested by funds: $3.2M → $8.39M (+$5.19M)

150% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 2

0.16% more ownership

Funds ownership: 0.72%0.88% (+0.16%)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

13% less funds holding

Funds holding: 2421 (-3)

33% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 9

Holders
21
Holders Change
-3
Holders Change %
-12.5%
% of All Funds
0.43%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
6
Increased
5
Reduced
2
Closed
9
Calls
Puts
Net Calls
Net Calls Change

COCP Hedge Fund Activity: Q2 2020 in Review

21 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Cocrystal Pharma (COCP) for Q2 2020, worth a combined $8.39M — up 162% from $3.2M a quarter earlier.

Sellers outnumbered buyers: 9 funds closed out of COCP and 6 opened new positions — a net loss of 3 holders — while 2 trimmed existing stakes and 5 added.

The largest buyer was Renaissance Technologies, adding an estimated $1.58M. The largest seller was Sabby Management, exiting entirely with an estimated $278K sold.

  • 21 institutional investors held Cocrystal Pharma (COCP) as of Q2 2020, down from 24 in Q1 2020.
  • Funds reported $8.39M of Cocrystal Pharma stock for Q2 2020, up 162% quarter-over-quarter.
  • 6 funds opened new Cocrystal Pharma positions in Q2 2020 and 9 closed out, a net change of -3 holders.
  • The largest Cocrystal Pharma buyer in Q2 2020 was Renaissance Technologies, an estimated $1.58M added.
  • The largest Cocrystal Pharma seller in Q2 2020 was Sabby Management, an estimated $278K sold.

Based on aggregated 13F filings for Q2 2020.